サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


The Global Radiopharmaceutical Market Forecast 2017-2027

世界の放射性医薬品市場予測2017−2027

レポート概要

用途別売上予測、用途別(オンコロジー、心臓内科、消化器内科、神経内分泌科、神経内科、腎臓内科、その他)、ラジオアイソトープ別(Tc-99, F-18, I-131, Lu-177, Y-90, Ga-68, Ga-67, Rb-82, I-123, I-125, I-111, その他)、線源別(サイクロトロン、核反応路)、エンドユーザー別(病院、画像診断センター、外来手術センター、がん研究施設)、地域別

放射性医薬品市場はどこへ向かっているのでしょうか。このセクターに関与している人に必要な情報として、データ、動向、事業機会、事業の将来見通しを分析して2027年までの収益の道筋を示します。

市場の優位性を維持するために

234ページのレポートに193の図、表、グラフを掲載しています。読み進めるにつれて、この領域で最も収益性の高い分野と市場の将来見通しが明らかになります。世界全体と地域別のレベルの売上予測のほか、財務データ、動向、事業機会を示します。拡大が続いている放射性医薬品市場には多くのビジネスチャンスが存在します。そのチャンスをどのように生かすことができるか、そのヒントがここにあります。

2027年までの予測やその他の分析データによって商業的見通しを明確にします:

  • 最近の業績、増加率、市場シェア
  • 独自の分析と事業の展望、動向
  • 定性分析(市場動態、推進要因、ビジネスチャンス、抑制要因、課題など)、製品プロフィール、商業的発展

放射性医薬品、用途別

  • オンコロジー
  • 心臓内科
  • 消化器内科
  • 神経内分泌科
  • 神経内科
  • 腎臓内科
  • その他

レポート詳細

目次

Table of Contents

1. Report Overview
1.1 Introduction
1.2 Why You Should Read This Report
1.3 Key Questions Answered by This Analytical Report
1.4 Who is This Report For?
1.5 Methodology
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain

2. Radiopharmaceutical Market Overview
2.1 Introduction
2.1.1 Market Definition
2.1.2 Market Taxonomy
2.2 Global Radiopharmaceutical Market Size and Forecast
2.3 Market Dynamics
2.3.1 Global Radiopharmaceutical Market: Drivers
2.3.1.1 Evolution towards Centralized Pharmacies
2.3.1.2 Increasing Number of PET and SPECT Scanners Globally
2.3.1.3 Minimizing the Dose in Paediatric Nuclear Imaging
2.3.1.4 Consolidation of Supply Chain
2.3.1.5 Growing Interest of Investors of Conventional Pharmaceutical Industries in the Therapeutic Area
2.3.1.6 Russian Supply Initiative for Mo-99
2.3.1.7 Increasing Domestic Radiopharmaceutical Production
2.3.1.8 Rising Incidence of Cancer and Cardiovascular Diseases
2.3.1.9 Diagnostics Remain a Key Focus of Radiopharmaceuticals Companies
2.3.1.10 Advancement in Radiotracers
2.3.2 Global Radiopharmaceutical Market: Restraints
2.3.2.1 Price Sensitivity and Lack of Specified Guidelines
2.3.2.2 Shorter Half Life of Radiopharmaceuticals Devices
2.3.2.3 Closing of Ageing Research Reactors Worldwide
2.3.3 Global Radiopharmaceutical Market: Opportunity
2.3.3.1 Alternative Diagnostic Radiopharmaceuticals Solutions
2.3.3.2 Lutetium
2.3.4 Global Radiopharmaceutical Market: Trends
2.3.4.1 Increasing focus of Manufacturers towards Diagnostic Tracers
2.3.4.2 Increasing Penetration of Radio-therapeutics
2.3.4.3 Fluoro-deoxy glucose (FDG)
2.3.4.4 Gallium-68
2.3.4.5 Nuclear pharmacies
2.3.4.6 Shortage of molybdenum-99/technetium-99m
2.4 Key Regulations

3. Global Radiopharmaceutical Market Analysis and Forecast, By Application
3.1 Introduction
3.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Application
3.2 Global Radiopharmaceutical Market Size and Forecast, By Application
3.2.1 Oncology Segment
3.2.2 Cardiology Segment
3.2.3 Gastroenterology
3.2.4 Neuroendocrinology
3.2.5 Neurology
3.2.6 Nephrology
3.2.7 Others
3.3 Global Radiopharmaceutical Market Attractiveness Index, By Application

4. Global Radiopharmaceutical Market Analysis and Forecast, By Radioisotope
4.1 Introduction
4.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Radioisotope
4.2 Global Radiopharmaceutical Market Size and Forecast, By Radioisotope
4.2.1 Tec. 99 Segment
4.2.2 F18 Segment
4.2.3 Iodine 131 Segment
4.2.4 Lutetium 177 Segment
4.2.5 Yttrium 90 Segment
4.2.6 Gallium 68 Segment
4.2.7 Gallium 67 Segment
4.2.8 Rubidium 82 Segment
4.2.9 Iodine 123 Segment
4.2.10 Iodine 125 Segment
4.2.11 Indium 111 Segment
4.2.12 Others Segment
4.3 Global Radiopharmaceutical Market Attractiveness Index, By Radioisotope

5. Global Radiopharmaceutical Market Analysis and Forecast, By Source
5.1 Introduction
5.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Source
5.2 Global Radiopharmaceutical Market Size and Forecast, By Source
5.2.1 Cyclotrons Segment
5.2.2 Nuclear Reactors Segment
5.3 Global Radiopharmaceutical Market Attractiveness Index, By Source

6. Global Radiopharmaceutical Market Analysis and Forecast, By End User
6.1 Introduction
6.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By End User
6.2 Global Radiopharmaceutical Market Size and Forecast, By End User
6.2.1 Hospitals Segment
6.2.2 Diagnostic Imaging Centres Segment
6.2.3 Ambulatory Surgical Centres Segment
6.2.4 Cancer Research Institute Segment
6.3 Global Radiopharmaceutical Market Attractiveness Index, By End User

7. Global Radiopharmaceutical Market Analysis and Forecast, By Region
7.1 Introduction
7.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Region
7.2 Global Radiopharmaceutical Market Size and Forecast, By Region
7.2.1 North America
7.2.2 Latin America
7.2.3 Western Europe
7.2.4 Eastern Europe
7.2.5 Asia Pacific
7.2.6 MEA
7.3 Global Radiopharmaceutical Market Attractiveness Index, By Region

8. North America Radiopharmaceutical Market Analysis and Forecast, 2016-2027
8.1 Introduction
8.1.1 North America Radiopharmaceutical Market
8.1.2 North America Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
8.2 North America Radiopharmaceutical Market Size and Forecast, By Country
8.2.1 The U.S. Radiopharmaceutical Market
8.2.2 Canada Radiopharmaceutical Market
8.3 North America Radiopharmaceutical Market Size and Forecast, By Application
8.4 North America Radiopharmaceutical Market Size and Forecast, By Radioisotope
8.5 North America Radiopharmaceutical Market Size and Forecast, By Source
8.6 North America Radiopharmaceutical Market Size and Forecast, By End User
8.7 North America Radiopharmaceutical Market Attractiveness Index
8.7.1 North America Radiopharmaceutical Market Attractiveness Index, By Country
8.7.2 North America Radiopharmaceutical Market Attractiveness Index, By Application
8.7.3 North America Radiopharmaceutical Market Attractiveness Index, By Radioisotope
8.7.4 North America Radiopharmaceutical Market Attractiveness Index, By Source
8.7.5 North America Radiopharmaceutical Market Attractiveness Index, By End User

9. Latin America Radiopharmaceutical Market Analysis and Forecast, 2016-2027
9.1 Introduction
9.1.1 Latin America Radiopharmaceutical Market
9.1.2 Latin America Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
9.2 Latin America Radiopharmaceutical Market Size and Forecast, By Country
9.2.1 Brazil Radiopharmaceutical Market
9.2.2 Mexico Radiopharmaceutical Market
9.2.3 Rest of Latin America Radiopharmaceutical Market
9.3 Latin America Radiopharmaceutical Market Size and Forecast, By Application
9.4 Latin America Radiopharmaceutical Market Size and Forecast, By Radioisotope
9.5 Latin America Radiopharmaceutical Market Size and Forecast, By Source
9.6 Latin America Radiopharmaceutical Market Size and Forecast, By End User
9.7 Latin America Radiopharmaceutical Market Attractiveness Index
9.7.1 Latin America Radiopharmaceutical Market Attractiveness Index, By Country
9.7.2 Latin America Radiopharmaceutical Market Attractiveness Index, By Application
9.7.3 Latin America Radiopharmaceutical Market Attractiveness Index, By Radioisotope
9.7.4 Latin America Radiopharmaceutical Market Attractiveness Index, By Source
9.7.5 Latin America Radiopharmaceutical Market Attractiveness Index, By End User

10. Western Europe Radiopharmaceutical Market Analysis and Forecast, 2017-2027
10.1 Introduction
10.1.1 Western Europe Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
10.2 Western Europe Radiopharmaceutical Market Size and Forecast, By Country
10.2.1 U.K. Radiopharmaceutical Market
10.2.2 France Radiopharmaceutical Market
10.2.3 Germany Radiopharmaceutical Market
10.2.4 Italy Radiopharmaceutical Market
10.2.5 Spain Radiopharmaceutical Market
10.2.6 Nordic Radiopharmaceutical Market
10.2.7 Benelux Radiopharmaceutical Market
10.2.8 Rest of Western Europe Radiopharmaceutical Market
10.3 Western Europe Radiopharmaceutical Market Size and Forecast, By Application
10.4 Western Europe Radiopharmaceutical Market Size and Forecast, By Radioisotope
10.5 Western Europe Radiopharmaceutical Market Size and Forecast, By Source
10.6 Western Europe Radiopharmaceutical Market Size and Forecast, By End User
10.7 Western Europe Radiopharmaceutical Market Attractiveness Index
10.7.1 Western Europe Radiopharmaceutical Market Attractiveness Index, By Country
10.7.2 Western Europe Radiopharmaceutical Market Attractiveness Index, By Application
10.7.3 Western Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope
10.7.4 Western Europe Radiopharmaceutical Market Attractiveness Index, By Source
10.7.5 Western Europe Radiopharmaceutical Market Attractiveness Index, By End User

11. Eastern Europe Radiopharmaceutical Market Analysis and Forecast, 2017-2027
11.1 Introduction
11.1.1 Eastern Europe Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
11.2 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Country
11.2.1 Russia Radiopharmaceutical Market
11.2.2 Poland Radiopharmaceutical Market
11.2.3 Rest of Eastern Europe Radiopharmaceutical Market
11.3 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Application
11.4 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Radioisotope
11.5 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Source
11.6 Eastern Europe Radiopharmaceutical Market Size and Forecast, By End User
11.7 Eastern Europe Radiopharmaceutical Market Attractiveness Index
11.7.1 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Country
11.7.2 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Application
11.7.3 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope
11.7.4 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Source
11.7.5 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By End User

12. Asia Pacific Radiopharmaceutical Market Analysis and Forecast, 2017-2027
12.1 Introduction
12.1.1 Asia Pacific Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
12.1.2 Asia Pacific Radiopharmaceutical Market, BPS Analysis, By Country
12.2 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Country
12.2.1 China Radiopharmaceutical Market
12.2.2 India Radiopharmaceutical Market
12.2.3 Australia and New Zealand Radiopharmaceutical Market
12.2.4 ASEAN Radiopharmaceutical Market
12.2.5 Japan Radiopharmaceutical Market
12.2.6 Rest of Asia Pacific Radiopharmaceutical Market
12.3 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Application
12.4 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Radioisotope
12.5 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Source
12.6 Asia Pacific Radiopharmaceutical Market Size and Forecast, By End User
12.7 Asia Pacific Radiopharmaceutical Market Attractiveness Index
12.7.1 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Country
12.7.2 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Application
12.7.3 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Radioisotope
12.7.4 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Source
12.7.5 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By End User

13. MEA Radiopharmaceutical Market Analysis and Forecast, 2017-2027
13.1 Introduction
13.1.1 MEA Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
13.2 MEA Radiopharmaceutical Market Size and Forecast, By Country
13.2.1 GCC Countries Radiopharmaceutical Market
13.2.2 South Africa Radiopharmaceutical Market
13.2.3 North Africa Radiopharmaceutical Market
13.2.4 Rest of MEA Radiopharmaceutical Market
13.3 MEA Radiopharmaceutical Market Size and Forecast, By Application
13.4 MEA Radiopharmaceutical Market Size and Forecast, By Radioisotope
13.5 MEA Radiopharmaceutical Market Size and Forecast, By Source
13.6 MEA Radiopharmaceutical Market Size and Forecast, By End User
13.7 MEA Radiopharmaceutical Market Attractiveness Index
13.7.1 MEA Radiopharmaceutical Market Attractiveness Index, By Country
13.7.2 MEA Radiopharmaceutical Market Attractiveness Index, By Application
13.7.3 MEA Radiopharmaceutical Market Attractiveness Index, By Radioisotope
13.7.4 MEA Radiopharmaceutical Market Attractiveness Index, By Source
13.7.5 MEA Radiopharmaceutical Market Attractiveness Index, By End User

14. Leading Companies in the Radiopharmaceutical Market
14.1 Competition Dashboard
14.2 Company Share Analysis
14.3 Company Profiles
14.3.1 Siemens AG
14.3.1.1 Basic Information
14.3.1.2 Company Overview
14.3.1.3 Product Offering
14.3.1.4 Financial Statements
14.3.1.5 Company Strategy
14.3.1.6 Key Developments
14.3.2 Eckert & Ziegler
14.3.2.1 Basic Information
14.3.2.2 Company Overview
14.3.2.3 Product Offering
14.3.2.4 Financial Statements
14.3.2.5 Key Developments
14.3.2.6 Company Strategy
14.3.3 Lantheus Medical Imaging, Inc.
14.3.3.1 Basic Information
14.3.3.2 Company Overview
14.3.3.3 Product Offering
14.3.3.4 Financial Statements
14.3.3.5 Key Developments
14.3.3.6 Company Strategy
14.3.4 Cardinal Health, Inc.
14.3.4.1 Basic Information
14.3.4.2 Company Overview
14.3.4.3 Product Offering
14.3.4.4 Financial Statements
14.3.4.5 Key Developments
14.3.4.6 Company Strategy
14.3.5 Bayer AG
14.3.5.1 Basic Information
14.3.5.2 Company Overview
14.3.5.3 Product Offering
14.3.5.4 Financial Statements
14.3.5.5 Key Developments
14.3.5.6 Company Strategy
14.3.6 Bracco Imaging S.P.A
14.3.6.1 Basic Information
14.3.6.2 Company Overview
14.3.6.3 Product Offering
14.3.6.4 Key Developments
14.3.6.5 Company Strategy
14.3.7 Nordion Inc.
14.3.7.1 Basic Information
14.3.7.2 Company Overview
14.3.7.3 Product Offering
14.3.7.4 Key Developments
14.3.7.5 Company Strategy
14.3.8 Advanced Accelerator Applications S.A.
14.3.8.1 Basic Information
14.3.8.2 Company Overview
14.3.8.3 Product Offering
14.3.8.4 Financial Statements
14.3.8.5 Key Developments
14.3.8.6 Company Strategy
14.3.9 Mallinckrodt PLC
14.3.9.1 Basic Information
14.3.9.2 Company Overview
14.3.9.3 Product Offering
14.3.9.4 Financial Statements
14.3.9.5 Key Developments
14.4 Other Companies of Interest in the Radiopharmaceutical Market

15. Conclusion

16. Glossary

Visiongain Report Sales Order Form
Associated Visiongain Reports
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

List of Figures
Figure 2.1 Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2015-2027
Figure 3.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Application Segment, 2015-2027
Figure 3.2: Global Radiopharmaceutical Market AGR (%) Comparison, By Application Segment, 2015-2027
Figure 3.4: Global Oncology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 3.5: Global Cardiology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 3.6: Global Gastroenterology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Segment, 2014-2027
Figure 3.7: Global Neuroendocrinology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 3.8: Global Neurology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 3.9: Global Nephrology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 3.10: Global Other Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 3.11: Global Radiopharmaceutical Market Attractiveness Index, By Application, 2017-2027
Figure 4.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Radioisotope Segment, 2015-2027
Figure 4.2: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Tec. 99 Segment, 2014-2027
Figure 4.3: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By F18 Segment, 2014-2027
Figure 4.4: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Iodine 131 Segment, 2014-2027
Figure 4.5: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Lutetium 177 Segment, 2014-2027
Figure 4.6: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Yttrium 90 Segment, 2014-2027
Figure 4.7: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Gallium 68 Segment, 2014-2027
Figure 4.8: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Gallium 67 Segment, 2014-2027
Figure 4.9: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Rubidium 82 Segment, 2014-2027
Figure 4.10: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Iodine 123 Segment, 2014-2027
Figure 4.11: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Iodine 125 Segment, 2014-2027
Figure 4.12: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Indium 111 Segment, 2014-2027
Figure 4.13: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Others Segment, 2014-2027
Figure 4.14: Global Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017-2027
Figure 5.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Source Segment, 2015-2027
Figure 5.2: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Cyclotrons Segment, 2014-2027
Figure 5.3: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Nuclear Reactors Segment, 2014-2027
Figure 5.4: Global Radiopharmaceutical Market Attractiveness Index, By Source, 2017-2027
Figure 6.1: Global Radiopharmaceutical Market AGR (%) Comparison, By End User Segment, 2015-2027
Figure 6.2: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Hospitals Segment, 2014-2027
Figure 6.3: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Diagnostic Imaging Centres Segment, 2014-2027
Figure 6.4: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Ambulatory Surgical Centres Segment, 2014-2027
Figure 6.5: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Cancer Research Institute Segment, 2014-2027
Figure 6.6: Global Radiopharmaceutical Market Attractiveness Index, By End User, 2017-2027
Figure 7.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Region, 2015-2027
Figure 7.2: North American Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 7.3: Latin American Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 7.4: Western European Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 7.5: Eastern European Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 7.6: Asia Pacific Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 7.7: MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 7.8: Global Radiopharmaceutical Market Attractiveness Index, By Region, 2017-2027
Figure 8.1: North American Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 8.2: North American Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015-2027
Figure 8.3: US Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 8.4: Canadian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 8.5: North American Radiopharmaceutical Market Attractiveness Index, By Country, 2017-2027
Figure 8.6: North American Radiopharmaceutical Market Attractiveness Index, By Application, 2017-2027
Figure 8.7: North American Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017-2027
Figure 8.8: North American Radiopharmaceutical Market Attractiveness Index, By Source, 2017-2027
Figure 8.9: North American Radiopharmaceutical Market Attractiveness Index, By End User, 2017-2027
Figure 9.1: Latin America Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 9.2: Latin America Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015-2027
Figure 9.3: Brazilian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 9.4: Mexican Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 9.5: Latin America Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Rest of Latin America, 2014-2027
Figure 9.6: Latin America Radiopharmaceutical Market Attractiveness Index, By Country, 2017-2027
Figure 9.7: Latin America Radiopharmaceutical Market Attractiveness Index, By Application, 2017-2027
Figure 9.8: Latin America Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017-2027
Figure 9.9: Latin America Radiopharmaceutical Market Attractiveness Index, By Source, 2017-2027
Figure 9.10: Latin America Radiopharmaceutical Market Attractiveness Index, By End User, 2017-2027
Figure 10.1: Western Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 10.2: Western Europe Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015-2027
Figure 10.3: UK Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 10.4: French Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 10.5: German Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 10.6: Italian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 10.7: Spanish Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 10.8: Nordic Radiopharmaceutical Market Value (US$m) Forecast and AGR (%),2014-2027
Figure 10.9: Benelux Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 10.10: Rest of Western Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 10.11: Western Europe Radiopharmaceutical Market Attractiveness Index, By Country, 2017-2027
Figure 10.12: Western Europe Radiopharmaceutical Market Attractiveness Index, By Application, 2017-2027
Figure 10.13: Western Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017-2027
Figure 10.14: Western Europe Radiopharmaceutical Market Attractiveness Index, By Source, 2017-2027
Figure 10.15: Western Europe Radiopharmaceutical Market Attractiveness Index, By End User, 2017-2027
Figure 11.1: Eastern Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 11.2: Eastern Europe Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015-2027
Figure 11.3: Russian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 11.4: Polish Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 11.5: Rest of Eastern Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 11.6: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Country, 2017-2027
Figure 11.7: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Application, 2017-2027
Figure 11.8: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017-2027
Figure 11.9: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Source, 2017-2027
Figure 11.10: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By End User, 2017-2027
Figure 12.1 Asia Pacific Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 12.2: Asia Pacific Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015-2027
Figure 12.3: Chinese Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 12.4: Indian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 12.5: Australia and New Zealand Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 12.6: ASEAN Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 12.7: Japanese Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 12.8: Rest of Asia Pacific Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 12.9: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Country, 2017-2027
Figure 12.10: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Application, 2017-2027
Figure 12.11: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017-2027
Figure 12.12: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Source, 2017-2027
Figure 12.13: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By End User, 2017-2027
Figure 13.1: MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 13.2: MEA Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015-2027
Figure 13.3: MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By GCC Countries, 2014-2027
Figure 13.4: South African Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 13.5: North African Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 13.6: Rest of MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
Figure 13.7: MEA Radiopharmaceutical Market Attractiveness Index, By Country, 2017-2027
Figure 13.8: MEA Radiopharmaceutical Market Attractiveness Index, By Application, 2017-2027
Figure 13.9: MEA Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017-2027
Figure 13.10: MEA Radiopharmaceutical Market Attractiveness Index, By Source, 2017-2027
Figure 13.11: MEA Radiopharmaceutical Market Attractiveness Index, By End User, 2017-2027
Figure 14.1: Leading Radiopharmaceutical Companies, By Market Share (%), 2016
Figure 14.2: Siemens Segment Percentage Split (2016)
Figure 14.3: Siemens Geographical Percentage Split (2016)
Figure 14.4: Eckert & Ziegler Segment Percentage Split
Figure 14.5: Eckert & Ziegler Geographic Percentage Split
Figure 14.6: Lantheus Medical Imaging, Inc. Segment Percentage Split
Figure 14.7: Lantheus Medical Imaging, Inc. Geographical Percentage Split
Figure 14.8: Cardinal Health, Inc. Segment Percentage Split
Figure 14.9: Cardinal Health, Inc. Geographical Percentage Split
Figure 14.10: Bayer AG Segment Percentage Split
Figure 14.11: Bayer AG Segment Geographical Percentage Split
Figure 14.12: Advanced Accelerator Applications S.A., Segment Percentage Split
Figure 14.13: Advanced Accelerator Applications S.A., Geographical Percentage Split
Figure 14.14: Mallinckrodt PLC Segment Percentage Split
Figure 14.15: Mallinckrodt PLC Geographical Percentage Split
Figure 15.1 Radiopharmaceutical Market Drivers and Restraints

List of Tables
Table 2.1 Global Radiopharmaceutical Market Segmentation
Table 3.1: Global Radiopharmaceutical Market Value (US$m) Forecast, By Radioisotope, 2016-2027
Table 3.2 Global Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
Table 4.1: Global Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
Table 4.1: Global Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
Table 5.1: Global Radiopharmaceutical Market Value (US$m) Forecast, By Radioisotope, 2016-2027
Table 6.1: Global Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
Table 7.1: Global Radiopharmaceutical Market Forecast, By Region ($m, AGR%, CAGR%) 2016-2027
Table 8.1: North American Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
Table 8.2: North American Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
Table 8.2: North American Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
Table 8.3: North American Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
Table 8.4: North American Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
Table 9.1: Latin America Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
Table 9.2: Latin America Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
Table 9.3: Latin America Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
Table 9.3: Latin America Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
Table 9.4: Latin America Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
Table 9.5: Latin America Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2017
Table 10.1: Western Europe Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
Table 10.2: Western Europe Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
Table 10.3: Western Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
Table 10.3: Western Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
Table 10.4: Western Europe Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
Table 10.5: Western Europe Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
Table 11.1: Eastern Europe Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
Table 11.2: Eastern Europe Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
Table 11.3: Eastern Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
Table 11.3: Eastern Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
Table 11.4: Eastern Europe Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
Table 11.5: Eastern Europe Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
Table 12.1: Asia Pacific Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
Table 12.2: Asia Pacific Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
Table 12.3: Asia Pacific Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
Table 12.3: Asia Pacific Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
Table 12.4: Asia Pacific Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
Table 12.5: Asia Pacific Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
Table 13.1: MEA Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
Table 13.2: MEA Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
Table 13.3: MEA Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
Table 13.3: MEA Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
Table 13.4: MEA Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
Table 13.5: MEA Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
Table 14.1: Radiopharmaceutical Market Competitive Overview
Table 14.2: Siemens AG Overview, 2016
Table 14.3: Siemens AG Financial Overview, 2014-2016
Table 14.4: Siemens Recent Developments
Table 14.5: Eckert & Ziegler Overview, 2016
Table 14.7: Eckert & Ziegler Recent Developments
Table 14.8: Lantheus Medical Imaging, Inc., Overview, 2016
Table 14.9 Lantheus Medical Imaging, Inc., Financial Overview 2013-2015
Table 14.10: Lantheus Medical Imaging, Inc., Recent Developments
Table 14.13: Cardinal Health Inc. Recent Developments
Table 14.14: Bayer AG, Overview, 2016
Table 14.15: Bayer AG, Financial Overview, 2014-2016
Table 14.16: Bayer AG Recent Developments
Table 14.17: Bracco Imaging S.P.A, Overview, 2016
Table 14.18: Bracco Imaging S.P.A, Recent Developments
Table 14.19: Nordion Inc., Overview, 2016
Table 14.20: Siemens Recent Developments
Table 14.21: Advanced Accelerator Applications S.A., Overview, 2016
Table 14.22: Advanced Accelerator Applications S.A., Financial Overview, 2013-2015
Table 14.23: Advanced Accelerator Applications S.A. Recent Developments
Table 14.24: Mallinckrodt PLC, Overview, 2016
Table 14.25: Mallinckrodt PLC, Overview, 2016
Table 14.26: Siemens Recent Developments
Table 14.27: Other Companies of Interest in the Radiopharmaceutical Market

発刊日

2017/07/03

体裁

PDF / 234ページ

販売価格

2,499GBP

発行

Visiongain

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。
※シングルユーザーライセンスのレポートは印刷不可、およびライセンス期間は1年となります。
※印刷可能のレポートをご希望の場合は、デパートメントライセンス(ライセンス期間1年、ユーザー数5人)をご検討ください。
※詳しくはお問い合わせください。

関連カテゴリ

医薬品原料・製剤

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE